News from NIAID-Supported Institutions
National Institute of Allergy and Infectious Diseases sent this bulletin at 01/10/2013 04:56 PM EST Here’s your periodic update on News from NIAID-Supported Institutions. The following links will take you to the institution’s press release:Drug Resistance: ‘Baby Steps’ Can Pay Off Big
January 9, 2013—Rice University
Measuring Genomic Response to Infection Leads to Earlier, Accurate Diagnoses
January 9, 2013—Duke
Modified Antibodies Trigger Immune Response, Point to Novel Vaccine Design Strategies
January 7, 2013—Whitehead Institute for Biomedical Research
New Compound Overcomes Drug-Resistant Staph Infection in Mice
January 7, 2013—University of Illinois
Pitt Enzyme Discovery May Lead to Better Tests for Tuberculosis
January 7, 2013—University of Pittsburgh Graduate School of Public Health
The Other Side of the Story
January 2, 2013—Harvard Medical School
Children’s Hospital/Pitt-Led Team Finds Molecule That Polices TB Lung Infection, Could Lead to Effective Vaccine
January 2, 2013—University of Pittsburgh School of Medicine
Invion Announces Initiation of Phase II Asthma Study
January 2, 2013—Invion Limited
Penn Team Developing New Class of Malaria Drugs Using Essential Calcium Enzyme
December 26, 2012—Perelman School of Medicine, University of Pennsylvania
Penn Team Mimicking a Natural Defense Against Malaria to Develop New Treatments
December 26, 2012—Perelman School of Medicine, University of Pennsylvania
New Technique Catalogs Lymphoma-Linked Genetic Variations
December 26, 2012—Johns Hopkins Medicine
Sarepta Therapeutics Enters Into Clinical Trial Agreement With the National Institutes of Health for Further Development of Influenza Drug
December 21, 2012—Sarepta Therapeutics, Inc.
First Ever “Atlas” of T Cells in Human Body
December 20, 2012—Columbia University Medical Center
CWRU, AstraZeneca Partner for New Tuberculosis Drug Trial in South Africa
December 20, 2012—Case Western Reserve University
.png)
No hay comentarios:
Publicar un comentario